18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Study summary

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedComputed Tomography and Fludeoxyglucose F-18

Plus 2 other study approaches.

Who it may be forCigarette Smoker · Current Smoker

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 9, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Andrei Iagaru

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Phase 2
Sponsor: Andrei Iagaru
Interventions being studied: Diagnostic Test: Computed Tomography; Drug: Fludeoxyglucose F-18; Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392; Diagnostic Test: Positron Emission Tomography (PET/CT)

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm
Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)
Current or former cigarette smoker, with \>= 20 pack years
Documented informed consent

Reasons someone may not be able to joinExclusion criteria

History or previous diagnosis of lung cancer
Cancer diagnosis within the last 5 years
Pregnant or nursing

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Stanford Cancer Institute Palo AltoPalo Alto, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 9, 2025. Always confirm current availability with the study team.

View original record ↗